Question 1

What's the right SSRI dose for anxiety, and how long is an adequate trial?

Accepted Answer

SSRIs show a clear linear dose-response for anxiety disorders, unlike depression where the benefit curve plateaus at moderate doses. Meta-analysis (Jakubovski et al., 2019, Depression and Anxiety; PMID 30479005) demonstrates higher SSRI doses deliver greater anxiolytic benefit with NNT 14-16, NNH 22-24 for side-effect dropout, and all-cause dropout actually decreasing at higher doses because therapeutic retention outweighs attrition. An adequate therapeutic trial is 8-12 weeks at full dose. Treatment failure defined by Delphi consensus as <40-50% symptom reduction on a validated scale or CGI-I >2 (Domschke et al., 2024, World Psychiatry; PMID 38214637). SNRIs do NOT show this linear dose-response; higher noradrenergic doses add side effects without additional anxiolytic gain.

Question 2

Are anxiety doses the same as depression doses for SSRIs?

Accepted Answer

SSRIs show a clear linear dose-response for anxiety disorders, unlike depression where the benefit curve plateaus at moderate doses. Meta-analysis (Jakubovski et al., 2019, Depression and Anxiety; PMID 30479005) demonstrates higher SSRI doses deliver greater anxiolytic benefit with NNT 14-16, NNH 22-24 for side-effect dropout, and all-cause dropout actually decreasing at higher doses because therapeutic retention outweighs attrition. An adequate therapeutic trial is 8-12 weeks at full dose. Treatment failure defined by Delphi consensus as <40-50% symptom reduction on a validated scale or CGI-I >2 (Domschke et al., 2024, World Psychiatry; PMID 38214637). SNRIs do NOT show this linear dose-response; higher noradrenergic doses add side effects without additional anxiolytic gain.

Question 3

When should I expect symptom relief vs full response (2-4 weeks vs 8-12 weeks)?

Accepted Answer

SSRIs show a clear linear dose-response for anxiety disorders, unlike depression where the benefit curve plateaus at moderate doses. Meta-analysis (Jakubovski et al., 2019, Depression and Anxiety; PMID 30479005) demonstrates higher SSRI doses deliver greater anxiolytic benefit with NNT 14-16, NNH 22-24 for side-effect dropout, and all-cause dropout actually decreasing at higher doses because therapeutic retention outweighs attrition. An adequate therapeutic trial is 8-12 weeks at full dose. Treatment failure defined by Delphi consensus as <40-50% symptom reduction on a validated scale or CGI-I >2 (Domschke et al., 2024, World Psychiatry; PMID 38214637). SNRIs do NOT show this linear dose-response; higher noradrenergic doses add side effects without additional anxiolytic gain.

Question 4

If there's no response by week 8, should I increase the dose or switch?

Accepted Answer

SSRIs show a clear linear dose-response for anxiety disorders, unlike depression where the benefit curve plateaus at moderate doses. Meta-analysis (Jakubovski et al., 2019, Depression and Anxiety; PMID 30479005) demonstrates higher SSRI doses deliver greater anxiolytic benefit with NNT 14-16, NNH 22-24 for side-effect dropout, and all-cause dropout actually decreasing at higher doses because therapeutic retention outweighs attrition. An adequate therapeutic trial is 8-12 weeks at full dose. Treatment failure defined by Delphi consensus as <40-50% symptom reduction on a validated scale or CGI-I >2 (Domschke et al., 2024, World Psychiatry; PMID 38214637). SNRIs do NOT show this linear dose-response; higher noradrenergic doses add side effects without additional anxiolytic gain.

PsychHQ

SSRI Dosing for Anxiety: Why Higher Doses Work, and How Long to Wait